文献速递皮肤肿瘤

血液或骨髓移植后皮肤恶性肿瘤的风险分层模型

Risk Stratification Models for Cutaneous Malignant Neoplasms After Blood or Marrow Transplant.
PubMed 文献 · JAMA Dermatol · 2026-01-01

本研究基于多机构纵向BMT幸存者研究(BMTSS)开发并验证了针对血液或骨髓移植(BMT)后发生皮肤恶性肿瘤的风险分层工具。纳入3448例移植后存活≥2年且无皮肤恶性肿瘤事件的受试者,模型纳入年龄、性别、既往皮肤癌、全身放疗、慢性GVHD等变量,15年时测试模型AUC对基底细胞癌(BCC)、鳞状细胞癌(SCC)和黑色素瘤分别为0.81、0.90和0.83,高风险组15年累积发病率显著高于低风险组。

要点

  • BMT后15年BCC、SCC和黑色素瘤的测试模型AUC分别为0.81、0.90和0.83。
  • 低风险组15年BCC/SCC/黑色素瘤累积发病率分别为2.4%、3.2%、0.8%。
  • 高风险组15年BCC/SCC/黑色素瘤累积发病率分别为13.3%、13.6%、4.4%。

核心结论

  • 风险分层模型在BMT受者中对后续BCC、SCC和黑色素瘤显示出优秀的预测性能,有助于识别高风险患者。

主要发现

  • 3448例受试者中,282例(8.2%)诊断为BCC,183例(5.3%)诊断为SCC,73例(2.1%)诊断为黑色素瘤。
  • BMT后15年,测试模型AUC对BCC为0.81(95% CI 0.76-0.85),对SCC为0.90(95% CI 0.86-0.93),对黑色素瘤为0.83(95% CI 0.74-0.90)。
  • 低风险组15年BCC、SCC和黑色素瘤累积发病率分别为2.4%(95% CI 1.5%-3.9%)、3.2%(95% CI 2.4%-4.2%)和0.8%(95% CI 0.4%-1.5%)。
  • 高风险组15年BCC、SCC和黑色素瘤累积发病率分别为13.3%(95% CI 11.6%-15.4%)、13.6%(95% CI 11.2%-16.5%)和4.4%(95% CI 3.2%-6.1%)。

关键数值与推荐

  • 风险分层模型候选变量包括:BMT时年龄、性别、种族、民族、既往皮肤恶性肿瘤、移植前单克隆抗体暴露、全身放疗、慢性移植物抗宿主病(GVHD)和移植后免疫抑制。
  • 基于临床有意义的风险分层评分阈值将个体分为低风险或高风险。
  • 模型开发与验证使用时间依赖的受试者工作特征曲线下面积(AUC),通过重复随机划分训练集和测试集,结果平均后形成最终模型。

临床怎么用

  • 该模型可用于识别BMT后皮肤恶性肿瘤高风险患者,以指导皮肤科监测和评估风险缓解策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Blood or marrow transplant (BMT) recipients are at increased risk of developing subsequent cutaneous malignant neoplasms. There is a need to develop risk stratification tools to identify those at highest risk to inform dermatologic surveillance and evaluate risk mitigation strategies. OBJECTIVE: To develop and validate a risk stratification tool for subsequent cutaneous malignant neoplasms among BMT recipients that incorporates readily available patient and treatment information. DESIGN, SETTING, AND PARTICIPANTS: This prognostic study included participants in the multi-institutional, longitudinal BMT Survivor Study (BMTSS), which included individuals who underwent autologous or allogeneic BMT from January 1, 1974, to December 31, 2014, at 1 of 3 participating sites in California, Minnesota, and Alabama and survived 2 or more years after BMT. The present cohort was restricted to individuals who underwent a single transplant and completed at least 1 BMTSS survey. Data were analyzed from December 3, 2024, to June 3, 2026. EXPOSURES: Risk stratification models included the following candidate variables: age at BMT, sex, race, ethnicity, prior cutaneous malignant neoplasm, pretransplant exposure to monoclonal antibodies, total body irradiation, chronic graft vs host disease, and posttransplant immunosuppression. MAIN OUTCOMES AND MEASURES: The main outcomes were incident basal cell carcinoma (BCC), squamous cell carcinoma (SCC), or melanoma after BMT, ascertained based on participant report with medical record validation when available. Models for risk stratification were developed and validated using time-dependent area under the receiver operating characteristic (AUC) curve with repeated random partitioning into training and testing cohorts. Results were averaged to make a final model. Individuals were classified into low or high risk for subsequent cutaneous malignant neoplasm based on clinically meaningful risk stratification score thresholds. RESULTS: Of the 3448 included BMTSS participants (1917 [55.6%] male; mean [SD] age at BMT, 41.9 [19.2] years) who were alive without a cutaneous malignant neoplasm event 2 years after BMT, 282 (8.2%) were diagnosed with BCC, 183 (5.3%) with SCC, and 73 (2.1%) with melanoma. At 15 years after BMT, the test model AUCs were 0.81 (95% CI, 0.76-0.85) for BCC, 0.90 (95% CI, 0.86-0.93) for SCC, and 0.83 (95% CI, 0.74-0.90) for melanoma. The 15-year cumulative incidence of BCC, SCC, and melanoma in the low-risk group was 2.4% (95% CI, 1.5%-3.9%), 3.2% (95% CI, 2.4%-4.2%), and 0.8% (95% CI, 0.4%-1.5%), respectively. In the high-risk group, the 15-year cumulative incidence of BCC, SCC, and melanoma was 13.3% (95% CI, 11.6%-15.4%), 13.6% (95% CI, 11.2%-16.5%), and 4.4% (95% CI, 3.2%-6.1%), respectively. CONCLUSIONS AND RELEVANCE: In this prognostic study, risk stratification models demonstrated excellent performance, highlighting potential utility for identifying BMT recipients who are at greatest risk of subsequent cutaneous malignant neoplasms.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Broman KK, Meng Q, Richman J, et al. Risk Stratification Models for Cutaneous Malignant Neoplasms After Blood or Marrow Transplant. JAMA Dermatol. 2026. PMID: 42584914. doi:10.1001/jamadermatol.2026.2763

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。